Analysts Set Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) PT at $55.80

Posted by Stanley Muller on Jun 22nd, 2026

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $55.80.

A number of research firms have weighed in on PTHS. Oppenheimer upped their price target on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Roth Mkm dropped their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Cantor Fitzgerald initiated coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price target for the company. Finally, Piper Sandler initiated coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price for the company.

Check Out Our Latest Research Report on PTHS

Pelthos Therapeutics Price Performance

PTHS opened at $29.00 on Monday. The company has a market capitalization of $100.92 million, a price-to-earnings ratio of -1.41 and a beta of 3.17. Pelthos Therapeutics has a 1-year low of $11.20 and a 1-year high of $54.29. The stock has a 50 day moving average price of $25.67. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41.

Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The business had revenue of $10.91 million for the quarter. Equities analysts anticipate that Pelthos Therapeutics will post -12.63 earnings per share for the current year.

Insider Buying and Selling at Pelthos Therapeutics

In related news, Director Todd C. Davis bought 35,948 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average price of $27.82 per share, for a total transaction of $1,000,073.36. Following the completion of the transaction, the director owned 75,834 shares in the company, valued at $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,228 shares of company stock worth $48,412 in the last three months. 12.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pelthos Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Knott David M Jr raised its stake in Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after purchasing an additional 1,792 shares in the last quarter. Geode Capital Management LLC raised its stake in Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after purchasing an additional 3,295 shares in the last quarter. Persistent Asset Partners Ltd raised its stake in Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares in the last quarter. Pale Fire Capital SE raised its stake in Pelthos Therapeutics by 59.5% during the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after purchasing an additional 4,819 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Pelthos Therapeutics during the fourth quarter valued at $343,000. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).